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Sterilization of Endoscopic Instruments
To the Editor In their study, Dr Epstein and colleagues1 found
that multiresistant bacterial strains were transmitted via en-
doscopic instruments, even though proper cleaning and dis-
infecting procedures were being followed. In an accompany-
ing Editorial, Drs Rutala and Weber2 raised the question of
whether such findings imply that sterilization rather than high-
level disinfection should become the standard for the process-
ing of complex, multichannel devices.
Rutala and Weber correctly pointed out that clinicians and
infection-control specialists face a dilemma: flexible endo-
scopes are heat-sensitive and cannot be sterilized with con-
ventional processes, such as steam sterilization. However, the
only low-temperature gaseous process cleared by the US Food
and Drug Administration (FDA) for many of these gastrointes-
tinal endoscopes is ethylene oxide sterilization, which has been
abandoned by many facilities because of the toxicity and car-
cinogenicity of ethylene oxide, the long sterilization times, and
aeration efficiency.
However, another FDA-cleared alternative for low-
temperature sterile processing does exist with liquid chemi-
cal sterilization. This technology has been available since the
late 1980s and has never been associated with a human infec-
tion when used properly.
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In Reply We are aware of only 1 liquid chemical sterilization pro-
cess that was cleared by the FDA in 1988, the Steris System 1
sterile processing. In December 2009, the FDA ordered all
health care facilities that used the System 1 processors to re-
place the unit with a legally marketed substitute.1 In April 2010,
the FDA approved the Steris System 1E Liquid Chemical Ster-
ilant (SS1E). The SS1E uses a chemical sterilant, peracetic acid,
to process devices. After treatment with peracetic acid, the
device is considered to be liquid chemically sterilized. How-
ever, the SS1E then rinses the processed device with exten-
sively treated, but not sterile, water to remove the chemical
residues to ensure the processed devices are safe for the
intended use.
The SS1E should be used only for processing heat-
sensitive semicritical and critical devices that are compatible
with the peracetic acid sterilant and processing system and can-
not be sterilized by other legally marketed traditional steril-
ization methods validated for that device.2 As a general rule,
the system should not be used to reprocess critical items be-
cause critical items should be sterile when used, and, with the
SS1E, the final processed device cannot be assured to be ster-
ile after it is rinsed. To our knowledge, there have been no in-
fections associated with the SS1E. We believe that all current
endoscope reprocessing methods should be investigated to
assess their capability to remove pathogens from gastrointes-
tinal endoscopes, especially duodenoscopes due to the eleva-
tor channel.
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